Lifeboat Foundation

Dr Haroldo Silva from SENS talks about ALT cancer in this short film.

As normal cells divide, the ends of their chromosomes (telomeres) progressively shorten until eventually the cells reach senescence or undergo apoptosis. Cancers, which disproportionally kill more individuals in the 65 years or above age group, often overcome this built-in replication limit by expressing the enzyme telomerase.

Continue reading “Uncovering the genetic basis of ALT (Alternative Lengthening of Telomeres) — Harold Silva” »

Time people rethought outdated ideas about biology and accepted that development and aging are not one way processess and they are amenable to intervention.

Scientists have announced they can now reverse the menopause in what is thought to be a major scientific breakthrough.

Trials claim to have ‘rejuvenated’ women’s ovaries using a blood treatment normally used to help wounds heal faster and have reversed menstrual cessation in multiple women, including 40-year-old woman who underwent the menopause five years ago.

Continue reading “Menopause reversed as scientists successfully ‘rejuvenate women’s ovaries’” »

https://www.youtube.com/watch?v=tKsTWM373xs

Even insurance companies are taking longevity seriously now!

Source: http://www.riskmindslive.com/will-rea…

Continue reading “Aubrey de Grey — Pushing back Death” »

Scientists at Emory University School of Medicine have found that the dietary supplement alpha lipoic acid (ALA) can stimulate telomerase, the enzyme that lengthens telomeres, with positive effects in a mouse model of atherosclerosis.

In human cells, shortened telomeres, the protective caps at the ends of chromosomes, are a sign of aging and also contribute to aging.

Continue reading “Anti-aging effects (in mice) of a dietary supplement called alpha lipoic acid” »

https://www.youtube.com/watch?v=N6eDDIyS_EA

Longevity sticker shock is holding back progress in rejuvenation biotechnology.

Filmed at BIL 2016 in Los Angeles.

New feature story on transhumanism out on Digital Trends:

Zoltan Istvan is the Transhumanist party leader and independent candidate for the forthcoming U.S. elections. And he wants you to live forever.

I’m super excited to share my first fiction since writing “The Transhumanist Wager” four years ago. Vice Motherboard has published this short story of mine on the challenge of AI becoming religious—and what that might mean for humanity. It’s a short read and the story takes place just a few years into the future. And yes, the happenings in this story could occur.

For the second installment of our series exploring the future of human augmentation, we bring you a story by the Transhumanist Party’s presidential candidate (and occasional Motherboard columnist), Zoltan Istvan. Though he’s spent most of the last year traveling the nation in a coffin-shaped bus, spreading the gospel of immortality and H+, he’s no stranger to fiction. His novel, The Transhumanist Wager, is about the impact of evolving beyond this mortal coil. This story is even bolder. Enjoy the always provocative, always entertaining, Zoltan Istvan. –the editor.

Continue reading “​The Jesus Singularity” »

I’m guessing you’d be like: surprised .

So, here’s the deal. My biohacker friends led by Peter Fedichev and Sergey Filonov in collaboration with my old friend and the longevity record holder Robert Shmookler Reis published a very cool paper. They proposed a way to quantitatively describe the two types of aging – negligible senescence and normal aging. We all know that some animals just don’t care about time passing by. Their mortality doesn’t increase with age. Such negligibly senescent species include the notorious naked mole rat and a bunch of other critters like certain turtles and clams to name a few. So the paper explains what it is exactly that makes these animals age so slowly – it’s the stability of their gene networks.

What does network stability mean then? Well, it’s actually pretty straightforward – if the DNA repair mechanisms are very efficient and the connectivity of the network is low enough, then this network is stable. So, normally aging species, such as ourselves, have unstable networks. This is a major bummer by all means. But! There is a way to overcome this problem, according to the proposed math model.

Continue reading “What would you say if I told you that aging happens not because of accumulation of stresses, but rather because of the intrinsic properties of the gene network of the organism?” »

Will Ichor Therapeutics be the first to clinic with a SENS based approach?

As I mentioned last week, earlier this year Fight Aging! invested a modest amount in the Ichor Therapeutics initiative to develop a treatment for macular degeneration, joining a number of other amateur and professional investors in helping to get this venture started. The approach taken here is based on the results of research carried out at the Methuselah Foundation and SENS Research Foundation over much of the past decade, funded by philanthropists and the support of our community of longevity science enthusiasts. This is how we succeed in building the future: medical science in the laboratory leads to medical development in startup companies, each new stage bringing treatments capable of repairing specific forms of age-related molecular damage that much closer to the clinic.

Ichor Therapeutics is one of a growing number of success stories to emerge from the SENS rejuvenation research community. Young scientists, advocates, and donors involved in earlier projects — years ago now — have gone on to build their own ventures, while retaining an interest in stepping up to do something meaningful to help bring an end to aging. Back in 2010, Kelsey Moody worked on the LysoSENS project to find ways to break down damaging metabolic waste in old tissues; fast-forward six years, and he is the now the CEO of a successful small biotechnology company with a great team, taking that very same technology and putting it to good use. I recently had the chance to ask Kelsey a few questions about the future of SENS rejuvenation research, as well as how the Ichor scientists intend to construct a new class of therapy for macular degeneration, one based on removing one of the root causes of the condition.

Continue reading “An Interview with Kelsey Moody of Ichor Therapeutics, Bringing a SENS Therapy for Macular Degeneration to the Clinic” »